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Abstract 25 
Studies have shown that administration of vasoactive intestinal peptide (VIP) in mice rescues 26 
them from lethal endotoxaemia and that this is correlated with decreased concentration of 27 
inflammatory cytokines. VIP has, therefore, been proposed as a novel anti-inflammatory which 28 
could be used in the treatment of Gram negative sepsis.  However, the effect of VIP has not been 29 
reported in mice infected with viable Gram negative bacteria. 30 
Here, we show that Salmonella enterica serovar Typhimurium 4/74 significantly increased 31 
expression of mRNA of a type 1 receptor (VPAC1) for anti-inflammatory vasoactive intestinal 32 
peptide (VIP) in murine ileum and mesenteric lymph nodes at day 6 post-infection (d6 pi) and in 33 
the spleen at d3 pi. When VIP (5 nmol/ml) was administered to S. Typhimurium-infected mice, 34 
there was a significant increase in the number of  S. Typhimurium cultured from murine faeces 35 
and ileum at d3 and 6 pi and in MLN and spleen at d3 dpi, compared to faeces and tissues 36 
examined from mice infected with S. Typhimurium (without VIP administration). Administration 37 
of VIP to S. Typhimurium-infected mice also altered the splenic architecture, resulting in a lack 38 
of discernable periarterial lymphoid sheaths or marginal zones at d6 pi but liver histology 39 
appeared similar on both d3 and d6 pi.  The effects of VIP administration were correlated with a 40 
significant decrease in expression of inflammatory cytokine mRNA, associated with systemic 41 
inflammatory response syndrome (SIRS) of bacteraemia and acute sepsis. 42 
We conclude that VIP inhibits expression of diagnostic/prognostic cytokine biomarkers of sepsis 43 
in S. Typhimurium-infected mice. However, this is occurred with a concomitant increase in 44 
Salmonella growth in tissues and increased bacterial shedding in faeces. Thus, VIP may have 45 
potential as an adjunctive therapy to antibiotics in sepsis. 46 
 47 
 48 
1.0 Introduction 49 
The bi-phasic model for human sepsis proposes a phase of uncontrolled production of 50 
inflammatory mediators, which leads to systemic inflammatory response syndrome (SIRS) (1-2), 51 
followed by a compensatory anti-inflammatory response syndrome (CARS) (3). The SIRS 52 
(acute) phase of sepsis is associated with high systemic concentrations of pro-inflammatory 53 
cytokines released by monocytes and macrophages, such as TNF-α, IL-1 and IL-6 (4). 54 
Intervention with anti-inflammatories has been proposed as a rational therapeutic avenue during 55 
SIRS but specific inhibition of IL-1β or TNF-α has failed (5), while broad ranging anti-56 
inflammatories, such as glucocorticoids, are also widely used in the treatment of sepsis but their 57 
effect is debateable probably due to timing of therapy, dosage and the development of steroid 58 
resistance by glucocorticoid receptors (6).    59 
In murine models of LPS-induced Gram negative sepsis, intra-peritoneal administration of low 60 
concentrations of VIP (5 nmol) prevented mortality and this was associated with inhibition of 61 
inflammatory cytokines (7).  In this regard, VIP may have potential in the treatment of Gram 62 
negative sepsis. The amino acid structure of VIP is highly conserved throughout the vertebrates 63 
and is identical in all mammals apart from guinea pigs (8). VIP exerts its biological effect via 64 
three G-protein coupled receptors; VIP receptor 1 (VPAC1), VPAC2 and a receptor which is 65 
also activated via the pituitary adenylate-cyclase activating polypeptide (PAC1). However, the 66 
immunosuppressive action of VIP on LPS-stimulated murine macrophages occurs via VPAC1 67 
(9) and therefore the interaction of VIP with VPAC1 during infection is worth further 68 
investigation. Increased VPAC1 expression was also reported in human peripheral blood 69 
monocytes following intravenous administration of LPS and this was correlated with increased 70 
VIP concentration in sera (10).  71 
However, using virulent S. Typhimurium (rather than LPS) we have shown that VIP promotes 72 
survival of S. Typhimurium within human monocytes, which is associated with inhibition of 73 
proinflammatory cytokines and increased survival of the infected cells (11). This may indicate 74 
that S. Typhimurium increases receptivity of monocytes to VIP, specifically to inhibit production 75 
of inflammatory mediators, thus gaining survival advantage 76 
The aim of this current study was to; (1) investigate the effect of a previously reported 77 
therapeutic concentration of VIP (5 nmol/ml) in mice infected with viable Salmonella rather than 78 
LPS. (2) investigate expression of the immunosuppressive VPAC1 receptor during infection; to 79 
examine the hypothesis that increased VPAC1 and VIP administration may correlate with 80 
decreased inflammatory cytokine expression and increased Salmonella survival 81 
 82 
2.0 Material and methods 83 
2.1 Reagents 84 
Unless otherwise stated all reagents were purchased from Sigma-Aldrich, Poole, Dorset UK. 85 
PCR and microarray reagents were purchased from Qiagen, Manchester, UK.  86 
2.2 Bioethics 87 
All studies were conducted following approval by local ethics committees and under UK Home 88 
Office license.  89 
2.3 Bacterial culture and strains.  90 
S. Typhimurium 4/74 were grown in Luria-Bertani (LB) broth (Life Technologies Ltd., Paisley, 91 
United Kingdom) for 18 h at 37°C under agitation. The bacteria were then sub-cultured in fresh 92 
LB broth for 4 h to late log phase (established by conventional counts of CFU). Prior to 93 
infection, bacteria were adjusted to a multiplicity of infection (MOI) of 10. 94 
2.4 Murine studies 95 
Female BALB/c mice, 6-10 weeks old, were divided into 3 groups as follows: Group 1, 12 mice 96 
were orally gavaged with 100 μl PBS and intra-peritoneally (i.p) injected with 50 μl of PBS 1h 97 
later. Group 2, 20 mice were orally gavauged with 1x 104 S. Typhimurium 4/74 in 100 μl PBS 98 
(sub-lethal dose) and injected i.p. with 50 μl of PBS 1h later. Group 3. 20 mice were orally 99 
gavauged with 100 μl PBS and injected i.p. with VIP (5 nmol in 50 μl PBS) 1h later. Half of 100 
each group of mice were euthanised by cervical dislocation on either day 3 (d3) or day 6 (6d) 101 
post-infection (pi). This experiment was performed in duplicate (N= 24 uninfected control, 40 S. 102 
Typhimurium infected and 40 S. Typhimurium infected/VIP. Spleen, ilea, mesenteric MLN and 103 
livers were aseptically removed and fixed in 10 % neutral buffered formalin (NBS) (histological 104 
analysis), or RNAlater (PCR analysis) or homogenised in sterile PBS using Griffith’s tubes for 105 
bacterial enumeration.  In addition, litter trays were changed daily and faecal pellets on 3 and 6 106 
dpi were collected for enumeration of S. Typhimurium. 107 
2.5 Histological studies 108 
Histological analysis of tissues was performed using standard techniques. Briefly, tissue fixed in 109 
NBS was washed in 70% ethanol prior to clearing and finally embedding in paraffin blocks. The 110 
blocks were sectioned using a microtome and stained by routine haematoxylin and eosin 111 
methods prior to examination using a conventional light microscope. 5 sections were examined 112 
per organ per mouse. 113 
2.6 Quantitative PCR analysis 114 
To investigate expression of VPAC1 and inflammatory cytokines in murine tissues, quantitative 115 
PCR was used. RNA was purified from murine tissue using Rneasy plus kits (Qiagen, Hilden, 116 
Germany). RNA quantity and quality were measured using a NanoDrop 8000 spectrophotometer 117 
(Thermo Scientific, Warrington, UK) and was converted into complimentary DNA (cDNA) 118 
using a SuperScipt first strand DNA synthesis kit (Invitrogen, Carlbad, CA, USA).  For 119 
quantitative PCR analysis, primers and probes were designed using a universal probe library 120 
(Roche Diagnostics, Mannheim, Germany). A PCR reaction volume (20 μl) consisting of 10 μl 121 
Light Cycler 480 Probes Master (Roche, Germany), 1 μm of each forward and reverse primer 122 
(Eurofins MWG, Operon, Germany) and 0.2 μl, labelled with Fluorescein and dark quencher 123 
dye. The total volume was adjusted to 20 μl using PCR water.  In negative control wells, PCR 124 
water was added instead of cDNA. Standard curves of target and reference genes were 125 
performed at dilution ranges between 1:10- 105.  Thermal cycles consisted of denaturing at 95 0C 126 
for 10 min and 40 cycles of sample amplification at 95 0C for 10 secs, 60 0C for 30 secs, 72 0C 127 
for 1 min and cooling at 40 0C for 30 secs, performed using a Roche applied sciences light cycler 128 
480 (Roche, Germany). All data was normalised to expression in uninfected mouse tissues and 129 
quantification was determined by comparison to the reference gene GAPDH, using the Pfaffl 130 
method (12).  All primers pairs used in the PCRs are shown in Table 1. 131 
Table 1. Forward and reverse primers and probes used in PCR reactions. 132 
2.7 Statistical Analysis 133 
Two-tailed unpaired student's t test or one-way ANOVA were performed to determine 134 
significant differences between different groups (control negative, S. Typhimurium infected, 135 
with or without VIP) using Graph Pad Prism software. Bonferroni's multiple comparisons test 136 
was applied to examine significant difference between the means of more than two groups, 137 
following ANOVA. Significance values were determined at the 95% confidence limit (P < 0.05). 138 
 139 
 140 
 141 
3.0 Results 142 
 143 
3.1 S. Typhimurium increases VPAC1 expression in murine tissues  144 
VPAC1 mRNA expression was significantly increased in murine tissue following S. 145 
Typhimurium infection at d3 and 6 pi. In the ileum VPAC1 expression was significantly 146 
increased at d3 pi (P <0.05) above control level. Administration of VIP also significantly 147 
increased VPAC1 expression (P <0.05) at d6 post-administration. A significant increase (P 148 
<0.05) in VPAC1 expression in S. Typhimurium-infected ileal tissue compared to ileal tissue 149 
from mice in which VIP was administered was measured at d3 pi only (Fig 1A). In the MLN, S. 150 
Typhimurium infection induced a significant increase in VPAC1 expression on both d3 and 6 pi 151 
above control expression (P <0.05) and on both days VPAC1 expression in infected MLN was 152 
significantly higher than VPAC1 expression in MLN of VIP administered mice (P <0.05), in 153 
which VPAC1 was not differentially expressed. S. Typhimurium also significantly increased 154 
VPAC1 expression in the spleens of mice at both d3 and 6 pi compared to VPAC1 expression in 155 
controls (P <0.05) (Fig 1B). Administration of VIP also significantly increased VPAC1 156 
expression in the spleen on both days 3 and 6 compared to VPAC1 expression in controls (P 157 
<0.05). However, a significant increase (P <0.05) in VPAC1 expression in S. Typhimurium-158 
infected spleen compared to spleens from mice in which VIP was administered was measured at 159 
6 dpi (Fig 1C). 160 
3.2 VPAC1 expression correlates with the numbers of S. Typhimurium recovered from 161 
tissues following VIP administration 162 
This trend in VPAC1 expression correlated with the numbers of S. Typhimurium recovered from 163 
tissues following VIP administration.  Therefore, following VIP administration, significantly 164 
more S. Typhimurium were isolated from the faeces (Fig 2A) and ileum (Fig 2B) of infected 165 
mice on both d3 and 6 pi compared to S. Typhimurium infected mice which had not been 166 
injected with VIP (P <0.05).  A significantly greater number of S. Typhimurium were also 167 
recovered from the MLN (Fig 2C) and spleen (Fig 2D) at 6 dpi following VIP administration, 168 
compared to S. Typhimurium-infected mice which had not been injected with VIP (P <0.05).   169 
3.3 VIP induces histological changes in the spleens of mice infected with S. Typhimurium 170 
 On d3 pi, splenic architecture was similar in S. Typhimurium infected mice, S. Typhimurium 171 
infected mice in which VIP was administered and uninfected mice, with tightly packed 172 
periarteriolar sheaths (PALS) and clear marginal zones (Fig 3A). However, administration of 173 
VIP to S. Typhimurium-infected mice altered the splenic architecture, resulting in a lack of 174 
discernable periarterial lymphoid sheaths or marginal zones by d6 pi (Fig 3B). On both d3 and 6 175 
pi, liver histology appeared similar in S. Typhimurium infected mice and in infected mice 176 
administered with VIP, with immune cell infiltrates of similar size and number (Fig 3C and D).   177 
The nature of the cellular infiltrate was also lymphocyte/neutrophil in infected tissues with or 178 
without VIP.  179 
3.4 VIP decreases cytokine mRNA expression in S. Typhimurium-infected tissues 180 
We studied the expression of prognostic cytokine markers of bacteraemia/sepsis in S. 181 
Typhimurium-infected mice and upregulation of these cytokines was mostly inhibited by VIP in 182 
tissue. 183 
     Generally, administration of VIP alone significantly increased expression of IL-1β and IL-6 184 
above control levels in the murine tissues we examined, and this was also generally the case 185 
when mice were infected with S. Typhimurium (Fig 4A-F). However, administration of VIP to S. 186 
Typhimurium-infected mice significantly inhibited upregulation of IL-1β in the ileum at d6 pi (P 187 
<0.01) (Fig 4A); in the MLN at both d3 (P <0.01) and 6 pi (P <0.05) (Fig 4B) and in the spleen 188 
at d3 pi (P <0.01) (Fig 4C). The same trend in IL-6 expression was observed; therefore VIP 189 
significantly inhibited IL-6 in the ileum at 6 dpi (P <0.01) (Fig 4D); in the MLN at both d3 (P 190 
<0.01) and 6 pi (P <0.05) (Fig 4E) and in the spleen at d3 pi (P <0.01) (Fig 4F).  191 
      Administration of VIP alone did not increase TNF-α expression above control levels in the 192 
ileum or MLN on either d3 or 6 post-administration but significantly increased TNF-α 193 
expression in the spleen at d6 (P <0.05) (Fig 5A-C). TNF-α expression was significantly 194 
increased (P <0.05) in the ilea of S. Typhimurium-infected mice at d6 pi above control levels (P 195 
<0.05) but no significant difference (P >0.05) in TNF-α expression was detected in the ilea of S. 196 
Typhimurium-infected mice in which VIP was administered (Fig 5A). S. Typhimurium 197 
significantly increased TNF-α expression in the ilea (P >0.01) and spleens (P >0.05) of mice at 198 
both d3 and 6 pi (Fig 5B and C) and VIP administration in S. Typhimurium-infected mice 199 
significantly decreased TNF-α expression in the MLN on both d3 (P <0.01) and 6 pi (P <0.01) 200 
(Fig 5B) and in the spleen at d3 pi (P >0.01) (Fig 5C).   201 
Administration of VIP alone significantly increased expression of IFN-γ above control levels in 202 
the ileum, MLN and spleen at d6 post-administration (P <0.05) (Fig 5D-F). S. Typhimurium 203 
infection induced significantly increased expression of IFN-γ at d6 pi in the ileum (P <0.01) (Fig 204 
5D) and MLN (P <0.01) (Fig 5E) and at d3 and 6 pi in the spleen (P <0.05) (Fig 5F). VIP 205 
significantly decreased IFN-γ expression in the ileum (P <0.01) (Fig 5D) and MLN (P <0.01) 206 
(Fig 5E) at d6 pi and spleen in the spleen at both d3 and 6 pi (P <0.05) (Fig 5F).   207 
    Administration of VIP alone significantly increased IL-10 mRNA expression above control 208 
levels only on d6 post-administration and only in splenic tissue (P <0.05) (Fig 6C).  S. 209 
Typhimurium infection induced significantly increased IL-10 expression in the ileum at both d3 210 
and 6 pi (P <0.01) (Fig 6A); in the MLN at d6 pi (P <0.01) (Fig 6B) and in the spleen at both 3 211 
and d6 pi (P <0.05) (Fig 6C).  VIP significantly decreased IL-10 upregulation in the ilea of S. 212 
Typhimurium-infected mice at both d3 and 6 pi (P <0.01) (Fig 6A); in the MLN at d6 pi (P 213 
<0.05) (Fig 6B) and in the spleen at both d3 and 6 pi (P <0.05) (Fig 6C). 214 
 215 
4.0 Discussion 216 
  An original study by Delgado et al (1999) reported that administration of 5 nmol of VIP 217 
significantly decreased mortality in mice in which Gram negative sepsis was induced by LPS and 218 
that this was associated with significant reduction in inflammatory cytokine production (7).  219 
Thus, VIP may have potential as a novel therapeutic in Gram negative bacteraemia and sepsis. In 220 
accordance with this, we show that VIP administration in S. Typhimurium-infected mice also 221 
inhibited upregulation of cytokines used as prognostic markers of sepsis (IL-1β, IL-6, TNF-α, 222 
IFN-γ and IL-10). However, in addition to this we show that S. Typhimurium 4/74 infection 223 
significantly increased VPAC1 expression in murine ileum, MLN and spleen and this was 224 
associated with a concurrent and significant increase in the number of S. Typhimurium isolated 225 
from these organs and in faeces, following VIP administration.  This may indicate that S. 226 
Typhimurium could utilise the VPAC1/VIP axis to increase survival by down-regulation of 227 
inflammatory mediators. Delgado et al., (2000) (9) reported that a VPAC1 antagonist was more 228 
efficient than a VPAC2 antagonist at inhibiting LPS-induced inflammatory mediators from 229 
murine macrophages. In our study, neither VPAC2 nor PAC1 were differentially expressed in 230 
any of the tissues we examined following infection (data not shown), which further supports the 231 
hypothesis that VPAC1 is the dominant immunosuppressive receptor that VIP acts upon. 232 
 Storka et al., (2013) (10) also reported a >30% increase in VPAC1 expression in monocytes 233 
isolated from human volunteers 24h after infusion of LPS and this was correlated with an 234 
increased concentration of VIP in plasma.  In our previous studies using viable S. Typhimurium, 235 
rather than LPS, we have shown that VIP down-regulates inflammatory mediators and increases 236 
Salmonella survival in human monocytes (11, 13) and murine macrophages (14); which may 237 
suggest that S. Typhimurium utilises the VIP/VPAC1 axis to increase survival in humans as well 238 
as mice.  We have shown that although LPS does increase cellular expression of VPAC1, this is 239 
much lower when compared to S. Typhimurium-infected cells (data not supplied). However, 240 
Salmonella have evolved complex gene networks (pathogenicity islands) which are involved in 241 
virulence and it is likely that some of these may influence VPAC1 expression. 242 
All of the cytokines we have studied in this work have been shown to be expressed during S. 243 
Typhimurium infection in vitro and in vivo and have been proposed as diagnostic and/or 244 
prognostic biomarkers of sepsis.  The SIRS (acute) phase of sepsis is associated with high 245 
systemic concentrations of pro-inflammatory cytokines released by monocytes and macrophages, 246 
such as TNF-α, IL-1 and IL-6 (4) and a study by Gogos et al. (2000) (15) reported that IL-10 247 
concentration was postively correlated with the onset of sepsis and that high IL-10/TNF- α ratio 248 
indicated a poor prognosis. High circulating levels of IL-6 and IL-10 have also been associated 249 
with mortaility in other studies (16, 17).  However, we show that during virulent infection, IL-10 250 
expression is increased by S. Typhimurium but this is not synergistically increased by VIP.  This 251 
is in contrast to a study by Delgado et al., (1999) (18) who reported a synergistic effect in mice, 252 
in vivo and in vitro, following LPS stimulation.  The difference we show is likely due to the use 253 
of viable bacteria and once again highlights the limitations in using LPS only. 254 
In the context of VIP, IFN-γ is the most studied of all. In murine J774 macrophages, VIP inhibits 255 
IFN-γ-induced reactive oxygen species (14) which leads to intracellular survival of wild type and 256 
Phop mutant S. Typhimurium. Normally, S. Typhimurium with a mutation of the Phop/PhoQ 257 
regulon are highly attenuated in macrophages (19) and are unable to survive in mice (20). A 258 
more recent study has also shown that VIP inhibited expression of IFN-γ and IFN-γ receptor 259 
genes, and upregulated expression of suppressor of cytokine signalling (SOCS) 1 and 2, in 260 
human monocytes infected with S. Typhimurium 4/74 (13).  Furthermore, in post-operative 261 
human sepsis, mortality has been associated with monocyte resistance to IFN-γ, which fails to 262 
increase the release of crucial monocyte cytokines (21) and pneumonia-induced sepsis has been 263 
reported to be associated with SNPs in IFN-γ genes (22). It is, therefore, likely that 264 
S.Typhimurium-induced inhibition of inflammatory cytokines (such as IFN-γ), via the 265 
VPAC1/VIP axis in murine tissues, had a profound effect on S. Typhimurium survival in vivo. 266 
  In conclusion, VIP decreases expression of cytokines which are hyper-expressed in sepsis. 267 
Therefore, VIP may have some therapeutic value. However, the decrease in cytokine expression 268 
is associated with an increase in the numbers of S. Typhimurium in tissue and shed in faeces; and 269 
S. Typhimurium may increase VPAC1 expression in tissue for this purpose. The therapeutic use 270 
of VIP would therefore need to be as an adjunctive therapy together with antibiotics and it is 271 
possible that intravenous infusion of VIP could reduce the prolonged hyper-expression of 272 
cytokines, which remain after antibiotic therapy has cleared the bacterial infection.  The 273 
longevity and concentration of VIP required for therapeutic effect needs further elucidation.  274 
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Figure Legends 350 
 351 
Figure 1.  S. Typhimurium 4/74 infection increases VPAC1 expression in vivo  352 
  S. Typhimurium infection significantly increased VPAC1 mRNA expression, above control 353 
expression, in the ileum at d3 pi (A); in the mesenteric lymph nodes (MLN) (B) and spleen (C) at 354 
both d3 and d6 pi. Administration of VIP (5 nmol) significantly increased VPAC1 mRNA 355 
expression, above control expression, in the ileum after d3  (A) and in the spleen (C) at both d3 356 
and d6 post-administration. S. Typhimurium infection also significantly increased VPAC1 357 
expression above expression measured in mice in which VIP was measured in the ileum (3d pi; P 358 
<0.05); MLN (d3 and d6 pi; P <0.05) and in the spleen (d6 pi; P <0.05).  Values shown are 359 
means obtained from duplicate experiments containing 12 uninfected (control) mice; 6 360 
euthanised on day 3 and 6 on day 6. Mean values are also shown for a second group of 20 mice 361 
infected with S. Typhimurium; 10 euthanised on day 3 and 10 on day 6 and a third group which 362 
were infected with S. Typhimurium and injected with VIP (5 nMol). N= 24 control, 40 infected 363 
and 40 infected/VIP. Fold changes are expressed as a comparison with mRNA expression 364 
measured in uninfected (control) mice, assigned an arbitrary value of 1. Error bars show standard 365 
deviation from the mean (SD). Linkage bars show significant differences in VPAC1 expression 366 
(P = 0.05) between murine tissues infected with S. Typhimurium or following VIP administration 367 
alone.  Asterisk  shows significant difference  at P =0.05 (*) between VPAC1 expression in 368 
murine tissue infected with S. Typhimurium or following VIP administration alone compared to 369 
unstimulated controls. Grey bar = VPAC1 expression in uninfected control mice; Black bar = 370 
VPAC1 expression following S. Typhimurium infection or VIP administration for 3 days. White 371 
bar = VPAC1 expression following S. Typhimurium infection or VIP administration for 6 days. 372 
Figure 2. VIP administration increases S. Typhimurium colonisation following 373 
administration of VIP 374 
Administration of VIP (5 nmol) to infected mice significantly increased the number of S. 375 
Typhimurium shed in feces (A) and isolated from the ileum (B) at d3 and d6 pi and also the 376 
number of S. Typhimurium isolated from the mesenteric lymph nodes (MLN) (C) and spleen (D) 377 
at d6 pi. Values shown are means of colony forming units per ml (CFU/ml).  Error bars show 378 
standard deviation from the mean (SD). Linkage bars show significant differences at P = 0.05 379 
between mice infected with S. Typhimurium and S. Typhimurium-infected mice in which VIP 380 
was administered. Black bar = d3 pi; White bar = d6 pi. 381 
 382 
 383 
Figure 3.  VIP alters the splenic architecture of S. Typhimurium infected mice 384 
(A) = Histological section of murine uninfected (control) spleens and d3 and 6 pi with S. 385 
Typhimurium or S.Typhimurium-infected/ VIP administered. Closed arrows highlight tightly 386 
packed periarteriolar sheaths (PALS) with clear marginal zones. Closed arrows show dispersed 387 
PALS in S. Typhimurium infected mice (6d pi) in which VIP was administered. (B) =  388 
Histological section of murine uninfected (control) livers at d3 and 6 pi with S. Typhimurium or 389 
S. Typhimurium-infected/VIP administered.  Closed arrows show similar cell infiltrate at d3 and 390 
6 pi in mice infected with S. Typhimurium and in S. Typhimurium-infected mice in which VIP 391 
was administered.  All sections were stained with haematoxylin and Eosin.  Images are 392 
representative of 5 sections analysed per organ per mouse. Scale bar (bottom left) = 50 μm. 393 
 394 
 395 
Figure 4. VIP inhibits expression of IL-1β and IL-6 mRNA in S. Typhimurium infected 396 
tissue 397 
Administration of VIP (5 nmol) alone significantly increased IL-1β and IL-6 mRNA expression 398 
above uninfected (control) levels in the ileum, MLN and spleen at  d6 post-administration (A-F), 399 
with the only exception being IL-6 in the MLN (E).   S. Typhimurium infection significantly 400 
increased expression of IL-1β and IL-6 mRNA above uninfected (control) levels in the ileum, 401 
MLN and spleen at d3 and/or 6 pi and this was inhibited when VIP was administered to S. 402 
Typhimurium-infected mice (A-F). Fold changes are expressed as a comparison with mRNA 403 
expression measured in uninfected (control) mice, assigned an arbitrary value of 1. Error bars 404 
show standard deviation from the mean (SD).  Linkage bars show significant differences (P = 405 
0.05) between IL-1β  and IL-6 mRNA expression in tissue from mice in infected with S. 406 
Typhimurium and S. Typhimurium-infected mice in which VIP was administered. Asterisk shows 407 
significant difference at P =0.05 (*) or P =0.01 (**) between IL-1β and IL-6 mRNA expression 408 
in tissue from mice in which VIP alone was administered, in mice infected with S. Typhimurium 409 
and S. Typhimurium-infected mice in which VIP was administered, compared to 410 
uninfected/unstimulated (control) mice. Grey bar = IL-1β or IL-6 mRNA expression in 411 
uninfected control mice; Black bar = IL-1β or IL-6 mRNA expression following S. Typhimurium 412 
infection or VIP administration for 3 days. White bar = IL-1β or IL-6 mRNA expression 413 
following S. Typhimurium infection or VIP administration for 6 days. 414 
 415 
 416 
 417 
Figure 5. VIP inhibits expression of TNFα and IFN-γ mRNA in S. Typhimurium infected 418 
tissue 419 
Administration of VIP (5 nmol) alone significantly increased TNFα mRNA expression only in 420 
the spleen at d6 post-administration (C) but significantly increased IFN-γ mRNA expression in 421 
the ileum, MLN and spleen at d6 pi (D-F).  S. Typhimurium infection significantly increased 422 
expression of TNFα and IFN-γ mRNA above uninfected (control) levels in the ileum, MLN and 423 
spleen at d3 and/or d6 pi and this was inhibited when VIP was administered to S. Typhimurium-424 
infected mice (A-F). 425 
Fold changes are expressed as a comparison with mRNA expression measured in uninfected 426 
(control) mice, assigned an arbitrary value of 1. Error bars show standard deviation from the 427 
mean (SD).  Linkage bars show significant differences (P = 0.05) between IL-1β  and IL-6 428 
mRNA expression in tissue from mice in infected with S. Typhimurium and S. Typhimurium-429 
infected mice in which VIP was administered. Asterisk shows significant difference at P =0.05 430 
(*) or P =0.01 (**) between IL-1β and IL-6 mRNA expression in tissue from mice in which VIP 431 
alone was administered, in mice infected with S. Typhimurium and S. Typhimurium-infected 432 
mice in which VIP was administered, compared to uninfected/unstimulated (control) mice. Grey 433 
bar = IL-1β or IL-6 mRNA expression in uninfected control mice; Black bar = IL-1β or IL-6 434 
mRNA expression following S. Typhimurium infection or VIP administration for 3 days. White 435 
bar = IL-1β or IL-6 mRNA expression following S. Typhimurium infection or VIP administration 436 
for 6 days. 437 
 438 
 439 
 440 
Figure 6. S. Typhimurium increases IL-10 expression but is not synergistically increased by 441 
VIIP 442 
  Administration of VIP (5 nmol) alone significantly increased TNFα mRNA expression only in 443 
the spleen at d6 post-administration (C). S. Typhimurium infection significantly increased 444 
expression of IL-10 mRNA above uninfected (control) levels in the ileum, MLN and spleen at 3 445 
and/or 6 dpi and this was inhibited when VIP was administered to S. Typhimurium-infected mice 446 
(A-F).  Fold changes are expressed as a comparison with mRNA expression measured in 447 
uninfected (control) mice, assigned an arbitrary value of 1. Error bars show standard deviation 448 
from the mean (SD).  Linkage bars show significant differences (P = 0.05) between IL-10 449 
expression in tissue from mice in infected with S. Typhimurium and S. Typhimurium-infected 450 
mice in which VIP was administered. Asterisk shows significant difference at P =0.05 (*) or P 451 
=0.01 (**) between IL-10 expression in tissue from mice in which VIP alone was administered, 452 
in mice infected with S. Typhimurium and S. Typhimurium-infected mice in which VIP was 453 
administered, compared to uninfected/unstimulated (control) mice. Grey bar = IL-10 mRNA 454 
expression in uninfected control mice; Black bar = IL-10 mRNA expression following S. 455 
Typhimurium infection or VIP administration for 3 days. White bar = IL-10 expression following 456 
S. Typhimurium infection or VIP administration for 6 days. 457 
 458 
 459 
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 463 
Table 1. Primer pairs used in qPCR analysis 464 
Table shows the primer pairs (forward and reverse sequences) used to determine expression of 465 
cytokines, VPAC1 and GAPDH (reference gene) in murine tissues. 466 
 467 
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 470 
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Table 1. Askar et al
Cytokine Forward primer Reverse primer
IL-6 5′-CAC AAG TCC 
GGA GAG GAG AC-3′
5′-CAG AAT TGC 
CAT TGC ACA AC-3′
TNF-α 5′-ACC CTC ACA 
CTC AGA TCA TCTT-3′
5′-GGT-TGT CTT 
TGA GAT CCA TGC-3′
IFN-γ 5′-CAG AGC CAG ATT
ATC TCT TTC TAC CTC
AGA C-3′
5′-CTT TTT CGC 
CTT GCT GTT GCT GAA G-3′
IL-1β 5′-CGC AGC AGC
ACA TCA ACA AGA GC-3′
5′-TGT CCT CAT 
CCT GGA AGG TCC ACG-3′
IL-10 5′-CAA CAT ACT GCT AAC 
CGA CTC CT-3′  
5′-TGA GGG TCT TCA GCT 
TCT CAC-3′
VPAC1 5′-GAT GTG GGA CAA CCT 
CAC CTG-3’
5′-TAG CCG TGA ATG GGG
GAA  AAC-3′
GAPDH 5′-ACA ATG AAT ACG GCT 
ACAG-3′
5′-GGT CCA GGG TTT
CTT ACT-3′
